Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2291]

The role of patient advocates in trial design, participation

Sarah Liptrott - Eurpean Institute of Oncology, Milan, Italy

The role of patient advocates in trial design, participation ( Sarah Liptrott - Eurpean Institute of Oncology, Milan, Italy )

Disruption of BAFF-BCR crosstalk in CLL

Dr Alexey Danilov - Knight Cancer Institute, Portland, USA

Disruption of BAFF-BCR crosstalk in CLL ( Dr Alexey Danilov - Knight Cancer Institute, Portland, USA )

ZUMA 1: CD19 CAR T cells for refractory NHL

Dr Yi Lin, Mayo Clinic - Rochester, MN, USA

$ZUMA 1: CD19 CAR T cells for refractory NHL ( Dr Yi Lin, Mayo Clinic - Rochester, MN, USA )$

Interim analysis of the JULIET study

Prof Gilles Salles - Université Claude Bernard, Lyon, France

Interim analysis of the JULIET study ( Prof Gilles Salles - Université Claude Bernard, Lyon, France )

400mg imatinib as good as 800mg for 10 year CML survival

Prof Rüdiger Hehlmann - European LeukemiaNet, Mannheim, Germany

400mg imatinib as good as 800mg for 10 year CML survival ( Prof Rüdiger Hehlmann - European LeukemiaNet, Mannheim, Germany )

Carfilzomib combinations in ENDEAVOR and FORTE

Prof Katja Weisel - University of Tübingen, Tübingen, Germany

Carfilzomib combinations in ENDEAVOR and FORTE ( Prof Katja Weisel - University of Tübingen, Tübingen, Germany )

Deep molecular response to gilteritinib in CHRYSALIS trial

Dr Jessica Altman - Robert H. Lurie Comprehensive Cancer Center of Northwestern...

Deep molecular response to gilteritinib in CHRYSALIS trial ( Dr Jessica Altman - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA )

Dual JAK/SYK inhibition in refractory NHL with cerdulatinib

Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA

$Dual JAK/SYK inhibition in refractory NHL with cerdulatinib ( Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA )$

Diverse T lymphocyte population fights leukaemia more effectively

Dr Michaela Kotrova - University Hospital Schleswig-Holstein, Kiel, Germany

Diverse T lymphocyte population fights leukaemia more effectively ( Dr Michaela Kotrova - University Hospital Schleswig-Holstein, Kiel, Germany )

Cerdulatinib demonstrates rapid responses in a phase 2 study for relapsed...

Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA

$Cerdulatinib demonstrates rapid responses in a phase 2 study for relapsed/refractory NHL ( Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA )$

Improving outcomes for oestrogen receptor positive breast cancer

Dr Giancarlo Pruneri - European Institute of Oncology, Milan, Italy

Improving outcomes for oestrogen receptor positive breast cancer ( Dr Giancarlo Pruneri - European Institute of Oncology, Milan, Italy )

European guidelines for breast cancer treatment

Dr Ciarán Nicholl - Research Centre Ispra, European Commission, Belgium

European guidelines for breast cancer treatment ( Dr Ciarán Nicholl - Research Centre Ispra, European Commission, Belgium )

More from ecancer